Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 5% biomarker prediction study in relapsing-remitting multiple sclerosis
ISRCTN57377482Phase 2Completed
- Sponsor
- Octapharma
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of Human normal immunoglobulin G in multiple sclerosis (MS), sponsored by Octapharma. Primary endpoints: Predictive value of Heidelberg assay panel and B-cell/antibody response panel, Clinical responder proportion and 3 more. Started Mar 2009; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN57377482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57377482.